LONDON, June 30, 2022 (GLOBE NEWSWIRE) – Element Materials Technology (Element), a global company for Testing, Inspection and Certification (ICT), has appointed Dr Elisabeth Lackner as Chief Scientific Officer (CSO).
In the newly created CSO role, Dr Lackner joins the Operations Council in ensuring that Element is positioned at the forefront of scientific thinking. It will be tasked with leading technical excellence and ensuring continued scientific rigor in the global affairs of more than 7,000 colleagues, with a focus on accelerating growth and services in Life Sciences.
Life Sciences now represents the largest final market for Element. Element has invested more than $ 400M over the past three years to develop its expertise and capacity for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts at 23 facilities in North America and the Americas. Europe. This significant change in pharmaceutical and medical testing capabilities by Element is part of its broader strategic shift to increase its global presence and create leadership positions in the end markets of Life Sciences and Related Technologies.
Dr. Lackner is a highly experienced pharmaceutical and biotechnology executive and a well-respected global thinking leader. He is joined by Vineta, a family office focused on long-term investments in Life Sciences, where he served as General Manager. Prior to that, he led the merger of ABF Pharmaceutical Services and GBA Group Pharma, serving as CEO of the GBA Pharma Division. As CEO, he transformed the company from a national vendor into an internationally trusted partner for the Pharma and Biotech industries. Dr. Lackner also serves as QP (Qualified Person) and is a respected consultant in the life sciences industry. He has a PhD in Pharmacy from the University of Vienna and a master’s degree in Tumor Biology. It holds external positions on several boards, including Marinomed and Rivean Capital.
“We are pleased to welcome Elisabeth to Element’s management team. Elisabeth joins us in a time of significant international expansion. She will play a key role in our ambitious growth strategy to support customers in the pharma markets,” medtech and life sciences, ”said Jo Wetz, CEO, Element. “In her new role as Chief Scientific Officer, Elisabeth will help us respond to and mobilize global trends affecting this industry by combining her proven scientific expertise and leadership skills. She joins an experienced international team, post that we continue to grow both organically and through strategic M&A. ”
Dr Elisabeth Lackner said: “It is exciting to be part of such an ambitious and professional team that is committed to building new global offerings across a wide range of services in the life science industry, including research and development. , diagnostics, analytical testing, manufacturing, production.regulatory assurance, calibration and validation.I look forward to supporting customers throughout the life cycle of their technology and products, from biopharmaceutical discovery and testing , with proof of materials and manufacturing.With the ever-increasing importance of advances in medical science and the importance of the development and commercialization of pharmaceutical and medical devices, Element is ideally positioned to play a role. even greater in supporting our clients in all life sciences and beyond.
Elisabeth will help Element create a global platform for Life Sciences, with integrated support for the medical products and medical devices industry. Element currently offers a wide range of services, including drug discovery; Biopharma tests (including E&L, microbiology and virology tests); environmental monitoring, calibration and validation; consumer product testing; Testing of medical devices (including testing of materials, E&L, microbiology, sterility, EMC and product safety); CRO services (including development of antimicrobial therapy, central laboratory capabilities and bioanalytical testing); CDMO; and formulation services.
Over the past three years Element has successfully acquired and integrated several companies focused on life sciences, including ALG, Avomeen, Arch Sciences, Impact Analytical, Orthokinetic, Nanosyn JMI Laboratories and Clinimark. More information is available at www.element.com/life-sciences.
For a high resolution image of Dr Elisabeth Lackner, please contact element@mc-services.eu
The Materials Element Technology Group is one of the world’s leading providers of testing, inspection and certification services for a diverse range of products, materials and technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in London, UK, Element’s 7,000 scientists, engineers and technologists, working in our global network of more than 200 laboratories, support customers from early R&D, through complex regulatory approvals and in production. ensuring that their products are safe, sustainable and reach the market. access.
In 2021, Element set out its new cutting-edge environmental commitments in the industry, pursuing science-based goals and committing to zero net emissions throughout its global business by 2035. These environmental commitments follow Element’s achievement. the highest ESG ranking in testing, inspection and certification industry by Sustainalytics, a global leader in ESG research and data.
For more information about Element, visit our website, connect with us on LinkedIn and Twitter and subscribe to our Youtube channel.
Elemental Materials TechnologyLee AndrewsE: Lee.Andrews@element.com
MC Services AGRaimund GabrielT: +49 89 210228 0UK: Shaun BrownM: +44 7867 515 918E: element@mc-services.eu
